Skip to main content
Clinical Trials/NL-OMON47572
NL-OMON47572
Completed
Phase 2

A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma. - SIRCCA

Sirtex Technology Pty Ltd0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
billiary tract cancer
Sponsor
Sirtex Technology Pty Ltd
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • a) Willing, able and mentally competent to provide written informed consent
  • b) Aged 18 years or older
  • c) Histologically or cytologically confirmed unresectable and/or non ablatable
  • intrahepatic cholangiocarcinoma
  • d) Liver\-only or liver predominant intrahepatic cholangiocarcinoma. Patients
  • are permitted to have loco\-regional lymph node involvement defined as: portal
  • LN \* 2 cm and/or para aortic LN \* 1\.5 cm in longest diameter, and/or up to 2
  • indeterminate lung lesions \< 1 cm if these lung lesions are PET negative.
  • e) Chemotherapy naïve. Adjuvant chemotherapy is not permitted
  • f) ECOG performance status 0 or 1,

Exclusion Criteria

  • a) Patients with only non\-measurable lesions in the liver according to RECIST
  • b) Incomplete recovery from previous liver surgery, e.g. unresolved biliary
  • tree obstruction or biliary sepsis or inadequate liver function
  • c) Biliary stenting in situ
  • d) Main trunk Portal Vein Thrombosis (PVT)
  • e) Ascites, even if controlled with diuretics. (A minor peri\-hepatic rim of
  • ascites detected at imaging is acceptable.)
  • f) Mixed HCC\-ICC disease.
  • g) History of prior malignancy. Exceptions include in\-situ carcinoma of the
  • cervix treated by cone\-biopsy/resection, non\-metastatic basal and/or squamous

Outcomes

Primary Outcomes

Not specified

Similar Trials